CTIS2023-503233-22-00进行中（未招募）1 期
01-AMO-CLA-BIO-22
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.0 个研究点目标入组 56 人开始时间: 2023年6月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.o medical condition.CTIS2024-513752-15-00Bial Portela & Ca S.A.48
招募中
1 期
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® Sourced from the European Union and United States in Healthy Male ParticipantsHealthy volunteersMedDRA version: 20.0Level: PTClassification code: 10031282Term: Osteoporosis Class: 100000004859CTIS2023-509749-11-00Xentria Inc.225
招募中
1 期
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients with Advanced Solid TumorsAdvanced Solid TumorsCTIS2024-513056-15-00Pharma Mar S.A.30
进行中（未招募）
1 期
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations of deucrictibant administered as single dose under fasting condition.Hereditary angioedema (HAE)MedDRA version: 23.1Level: PTClassification code: 10019860Term: Hereditary angioedema Class: 100000004850CTIS2024-511196-15-00Pharvaris Netherlands B.V.14
进行中（未招募）
1 期
A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEALTHY SUBJECTS.Cardiac arrhythmiasMedDRA version: 20.0Level: HLGTClassification code: 10007521Term: Cardiac arrhythmias Class: 10007541CTIS2023-509086-20-00Armgo Pharma Inc.8